症例報告: 治療に抵抗するうつ病の管理において,鼻内エスケタミンと生成性人工知能の組み合わせ
Alexandre Fraichot1, Sophie Favre1, Hélène Richard-Lepouriel1,2
1Mood and Anxiety Disorder Unit, Psychiatric Specialties Service, Department of Psychiatry, Geneva University Hospital, Geneva, Switzerland.
Frontiers in psychiatry
|September 2, 2025
まとめ
この研究は,鼻内エスケタミンと人工知能のツールの組み合わせが 鬱の治療に役立つことを示しています. 患者はAIで生成された画像と解釈を使って 進行を追跡し 鬱から回復しました
科学分野:
- 精神科
- デジタル・ヘルス
- 薬理学について
背景:
- 内鼻エスケタミンは,治療に抵抗するうつ病に対する迅速な作用の抗うつ剤です.
- 人工知能 (AI) は医学における新興ツールであり,精神医学における応用に関する研究は限られている.
関連する概念動画
01:23Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
01:30Electroconvulsive Therapy
182
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
182